vorinostat has been researched along with Malignant Melanoma in 22 studies
Vorinostat: A hydroxamic acid and anilide derivative that acts as a HISTONE DEACETYLASE inhibitor. It is used in the treatment of CUTANEOUS T-CELL LYMPHOMA and SEZARY SYNDROME.
vorinostat : A dicarboxylic acid diamide comprising suberic (octanedioic) acid coupled to aniline and hydroxylamine. A histone deacetylase inhibitor, it is marketed under the name Zolinza for the treatment of cutaneous T cell lymphoma (CTCL).
| Excerpt | Relevance | Reference |
|---|---|---|
| "Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma." | 9.19 | Phase II trial of vorinostat in advanced melanoma. ( Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014) |
| "Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma." | 9.16 | Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. ( Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A, 2012) |
| "Employing human melanoma cell lines A-375, Hs-294T and G-361, we determined the effect of vorinostat and/or EGCG on 1) growth/viability and colony formation, 2) apoptosis, and 3) the critical molecules involved in cell cycle and apoptosis regulation." | 7.76 | Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). ( Nihal, M; Roelke, CT; Wood, GS, 2010) |
| "Vorinostat is a small molecule inhibitor of class I and II histone deacetylases with preclinical activity in melanoma." | 5.19 | Phase II trial of vorinostat in advanced melanoma. ( Adams, PD; Alpaugh, RK; Haas, NB; Hotte, S; Litwin, S; Martin, LP; McBryan, T; McWhirter, E; Oza, A; Polintan, R; Quirt, I; vonMehren, M; Wang, L; Zweibel, J, 2014) |
| "Marked synergy of marizomib and vorinostat was seen in tumor cell lines derived from patients with NSCLC, melanoma and pancreatic carcinoma." | 5.16 | Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination. ( Drabkin, HA; Gemmill, RM; Lay, A; Lee, L; Lloyd, GK; Longenecker, A; McConkey, DJ; Millward, M; Neuteboom, ST; Palladino, MA; Price, T; Sharma, G; Spear, MA; Spencer, A; Sukumaran, S; Sweeney, C; Townsend, A, 2012) |
| " With the goal of selective delivery of the HDACi to melanoma cells, we incorporated the benzamide, a high affinity melanin-binding template, into the design of HDACi to generate a new series of compounds 10a-b and 11a-b which display high potency towards HDAC1 and HDAC6." | 3.85 | Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors. ( Ahluwalia, K; Oyelere, AK; Raji, I, 2017) |
| "Matrigel and Collagen invasion assays were performed to evaluate the effect of several HDACi (Butyrate, Trichostatin A, Valproic acid and Vorinostat) on two human melanoma cell line invasion (A375 and HT-144)." | 3.83 | Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity. ( Andrade, R; Aréchaga, J; Arluzea, J; De Wever, O; Díaz-Núñez, M; Díez-Torre, A; Silió, M, 2016) |
| "Employing human melanoma cell lines A-375, Hs-294T and G-361, we determined the effect of vorinostat and/or EGCG on 1) growth/viability and colony formation, 2) apoptosis, and 3) the critical molecules involved in cell cycle and apoptosis regulation." | 3.76 | Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG). ( Nihal, M; Roelke, CT; Wood, GS, 2010) |
| "Currently, dacarbazine (DTIC) is the only approved systemic treatment for metastatic malignant melanoma." | 3.74 | Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines. ( Engebraaten, O; Engesaeter, BO; Fodstad, O; Lillehammer, T; Maelandsmo, GM; Prasmickaite, L, 2007) |
| "To investigate their potential use as cancer testis antigen (CTA) vaccines, we studied the expression of 12 cancer testis (CT) genes in 20 LCL by RT-PCR." | 1.39 | EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors. ( Held, G; Kaddu-Mulindwa, D; Kubuschok, B; Neumann, F; Pfreundschuh, M; Preuss, KD; Roemer, K; Widmann, T; Zwick, C, 2013) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (13.64) | 29.6817 |
| 2010's | 15 (68.18) | 24.3611 |
| 2020's | 4 (18.18) | 2.80 |
| Authors | Studies |
|---|---|
| Raji, I | 1 |
| Ahluwalia, K | 1 |
| Oyelere, AK | 1 |
| Shen, S | 1 |
| Hadley, M | 1 |
| Ustinova, K | 1 |
| Pavlicek, J | 1 |
| Knox, T | 1 |
| Noonepalle, S | 1 |
| Tavares, MT | 1 |
| Zimprich, CA | 1 |
| Zhang, G | 1 |
| Robers, MB | 1 |
| Bařinka, C | 1 |
| Kozikowski, AP | 1 |
| Villagra, A | 1 |
| Li, X | 2 |
| Yu, W | 1 |
| Yang, J | 1 |
| Chen, Y | 2 |
| Qian, X | 1 |
| Wang, J | 1 |
| Wang, Y | 1 |
| Ji, J | 1 |
| Huijberts, S | 2 |
| Wang, L | 3 |
| de Oliveira, RL | 1 |
| Rosing, H | 1 |
| Nuijen, B | 2 |
| Beijnen, J | 1 |
| Bernards, R | 2 |
| Schellens, J | 1 |
| Wilgenhof, S | 1 |
| Gassenmaier, M | 1 |
| Rentschler, M | 1 |
| Fehrenbacher, B | 1 |
| Eigentler, TK | 1 |
| Ikenberg, K | 1 |
| Kosnopfel, C | 1 |
| Sinnberg, T | 1 |
| Niessner, H | 1 |
| Bösmüller, H | 1 |
| Wagner, NB | 1 |
| Schaller, M | 1 |
| Garbe, C | 1 |
| Röcken, M | 1 |
| Wu, R | 1 |
| Wang, C | 1 |
| Li, Z | 2 |
| Xiao, J | 1 |
| Li, C | 1 |
| Wang, X | 1 |
| Kong, P | 1 |
| Cao, J | 1 |
| Huang, F | 1 |
| Huang, Y | 1 |
| Yang, D | 1 |
| Zhang, H | 1 |
| Mai, J | 1 |
| Feng, G | 1 |
| Deng, R | 1 |
| Zhu, X | 1 |
| Fiziev, P | 1 |
| Akdemir, KC | 1 |
| Miller, JP | 1 |
| Keung, EZ | 1 |
| Samant, NS | 1 |
| Sharma, S | 1 |
| Natale, CA | 1 |
| Terranova, CJ | 1 |
| Maitituoheti, M | 1 |
| Amin, SB | 1 |
| Martinez-Ledesma, E | 1 |
| Dhamdhere, M | 1 |
| Axelrad, JB | 1 |
| Shah, A | 1 |
| Cheng, CS | 1 |
| Mahadeshwar, H | 1 |
| Seth, S | 1 |
| Barton, MC | 1 |
| Protopopov, A | 1 |
| Tsai, KY | 1 |
| Davies, MA | 1 |
| Garcia, BA | 1 |
| Amit, I | 1 |
| Chin, L | 1 |
| Ernst, J | 1 |
| Rai, K | 1 |
| Lee, J | 1 |
| Ko, J | 1 |
| Yi, JY | 1 |
| Leite de Oliveira, R | 1 |
| Bosdriesz, E | 1 |
| Pencheva, N | 1 |
| Brunen, D | 1 |
| Bosma, A | 1 |
| Song, JY | 1 |
| Zevenhoven, J | 1 |
| Los-de Vries, GT | 1 |
| Horlings, H | 1 |
| Beijnen, JH | 1 |
| Schellens, JHM | 1 |
| Neumann, F | 1 |
| Kaddu-Mulindwa, D | 1 |
| Widmann, T | 1 |
| Preuss, KD | 1 |
| Held, G | 1 |
| Zwick, C | 1 |
| Roemer, K | 1 |
| Pfreundschuh, M | 1 |
| Kubuschok, B | 1 |
| Lai, F | 1 |
| Guo, ST | 1 |
| Jin, L | 1 |
| Jiang, CC | 1 |
| Wang, CY | 1 |
| Croft, A | 1 |
| Chi, MN | 1 |
| Tseng, HY | 1 |
| Farrelly, M | 1 |
| Atmadibrata, B | 1 |
| Norman, J | 1 |
| Liu, T | 1 |
| Hersey, P | 1 |
| Zhang, XD | 1 |
| Haas, NB | 1 |
| Quirt, I | 1 |
| Hotte, S | 1 |
| McWhirter, E | 1 |
| Polintan, R | 1 |
| Litwin, S | 1 |
| Adams, PD | 1 |
| McBryan, T | 1 |
| Martin, LP | 1 |
| vonMehren, M | 1 |
| Alpaugh, RK | 1 |
| Zweibel, J | 1 |
| Oza, A | 1 |
| Uhlenbrock, F | 1 |
| Hagemann-Jensen, M | 1 |
| Kehlet, S | 1 |
| Andresen, L | 1 |
| Pastorekova, S | 1 |
| Skov, S | 1 |
| Díaz-Núñez, M | 1 |
| Díez-Torre, A | 1 |
| De Wever, O | 1 |
| Andrade, R | 1 |
| Arluzea, J | 1 |
| Silió, M | 1 |
| Aréchaga, J | 1 |
| Nihal, M | 1 |
| Roelke, CT | 1 |
| Wood, GS | 1 |
| Landreville, S | 1 |
| Agapova, OA | 1 |
| Matatall, KA | 1 |
| Kneass, ZT | 1 |
| Onken, MD | 1 |
| Lee, RS | 1 |
| Bowcock, AM | 1 |
| Harbour, JW | 1 |
| Millward, M | 1 |
| Price, T | 1 |
| Townsend, A | 1 |
| Sweeney, C | 1 |
| Spencer, A | 1 |
| Sukumaran, S | 1 |
| Longenecker, A | 1 |
| Lee, L | 1 |
| Lay, A | 1 |
| Sharma, G | 1 |
| Gemmill, RM | 1 |
| Drabkin, HA | 1 |
| Lloyd, GK | 1 |
| Neuteboom, ST | 1 |
| McConkey, DJ | 1 |
| Palladino, MA | 1 |
| Spear, MA | 1 |
| Gowda, R | 1 |
| Madhunapantula, SV | 1 |
| Desai, D | 1 |
| Amin, S | 1 |
| Robertson, GP | 1 |
| Shao, Y | 1 |
| Aplin, AE | 1 |
| Facchetti, F | 1 |
| Previdi, S | 1 |
| Ballarini, M | 1 |
| Minucci, S | 1 |
| Perego, P | 1 |
| La Porta, CA | 1 |
| Munshi, A | 1 |
| Tanaka, T | 1 |
| Hobbs, ML | 1 |
| Tucker, SL | 1 |
| Richon, VM | 1 |
| Meyn, RE | 1 |
| Lillehammer, T | 1 |
| Engesaeter, BO | 1 |
| Prasmickaite, L | 1 |
| Maelandsmo, GM | 1 |
| Fodstad, O | 1 |
| Engebraaten, O | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| HDAC Inhibitor Vorinostat in Resistant BRAF V600 Mutated Advanced Melanoma[NCT02836548] | Phase 1/Phase 2 | 22 participants (Anticipated) | Interventional | 2016-06-30 | Recruiting | ||
| A Phase II Study of Vorinostat in Patients With Advanced Melanoma[NCT00121225] | Phase 2 | 32 participants (Actual) | Interventional | 2005-09-30 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Blood specimens were collected from participants on Day 1 Cycle 1 prior to treatment (baseline), Day 1 3-4 hours following Vorinostat ingestion, Day 8 and Day 15. VEGF serum concentrations were detected using the Luminex multiplexed assay, where the median fluorescence intensity results were analyzed by a weighted five-parameter logistic method. The values were averaged across all time points per participant. (NCT00121225)
Timeframe: Baseline, Day 1, Day 8 and Day 15
| Intervention | pg (Mean) |
|---|---|
| Arm 1 Vorinostat | 203 |
Per Response Evaluation Criteria in Solid Tumours Criteria (RECIST v1.0) for target lesions and are assessed by MRI: Complete Response (CR), disappearance of all target lesions; Partial Response (PR), at least 30% decrease in sum of longest diameter of target lesions; Objective Response (OR) = CR+ PR. (NCT00121225)
Timeframe: Up to 5 years
| Intervention | participants (Number) |
|---|---|
| Arm I | 2 |
(NCT00121225)
Timeframe: Up to 5 years
| Intervention | months (Median) |
|---|---|
| Arm 1 Vorinostat | 4 |
Macro H2A and HP1 expression levels were compared through analysis of log fold changes in antibody expression in a multivariate general linear model between progressive disease and stable disease outcomes. (NCT00121225)
Timeframe: Baseline and day 15
| Intervention | log fold change (Mean) | ||
|---|---|---|---|
| MacroH2A1.1 | MacroH2A1.2 | HP1 | |
| Arm 1 Vorinostat | 0.149 | -0.748 | -0.077 |
Participants were assessed for p53 allelic variation at baseline (NCT00121225)
Timeframe: Baseline
| Intervention | participants (Number) | |
|---|---|---|
| Wild Type | Mutant | |
| Arm 1 Vorinostat | 20 | 11 |
3 trials available for vorinostat and Malignant Melanoma
| Article | Year |
|---|---|
Vorinostat in patients with resistant
Topics: Antineoplastic Combined Chemotherapy Protocols; Drug Administration Schedule; Drug Resistance, Neopl | 2020 |
Phase II trial of vorinostat in advanced melanoma.
Topics: Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Biomarkers; Disease-Free Survival; Female; Fi | 2014 |
Phase 1 clinical trial of the novel proteasome inhibitor marizomib with the histone deacetylase inhibitor vorinostat in patients with melanoma, pancreatic and lung cancer based on in vitro assessments of the combination.
Topics: Adult; Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Carci | 2012 |
19 other studies available for vorinostat and Malignant Melanoma
| Article | Year |
|---|---|
Design, synthesis and evaluation of antiproliferative activity of melanoma-targeted histone deacetylase inhibitors.
Topics: Acetylation; Animals; Benzamides; Cell Line, Tumor; Cell Proliferation; Cell Survival; Drug Design; | 2017 |
Discovery of a New Isoxazole-3-hydroxamate-Based Histone Deacetylase 6 Inhibitor SS-208 with Antitumor Activity in Syngeneic Melanoma Mouse Models.
Topics: Animals; Catalytic Domain; CD8-Positive T-Lymphocytes; Cell Line, Tumor; Drug Discovery; Histone Dea | 2019 |
Microneedle patch with "spongy coating" to co-load multiple drugs to treat multidrug-resistant melanoma.
Topics: Carboplatin; Humans; Melanoma; Pharmaceutical Preparations; Polyethyleneimine; Polymethyl Methacryla | 2022 |
Expression of DNA Methyltransferase 1 Is a Hallmark of Melanoma, Correlating with Proliferation and Response to B-Raf and Mitogen-Activated Protein Kinase Inhibition in Melanocytic Tumors.
Topics: Cell Line, Tumor; Cell Proliferation; DNA; Histone Deacetylase Inhibitors; Humans; Melanocytes; Mela | 2020 |
SOX2 promotes resistance of melanoma with PD-L1 high expression to T-cell-mediated cytotoxicity that can be reversed by SAHA.
Topics: Animals; Antineoplastic Agents; B7-H1 Antigen; CD8-Positive T-Lymphocytes; Drug Resistance, Neoplasm | 2020 |
Systematic Epigenomic Analysis Reveals Chromatin States Associated with Melanoma Progression.
Topics: Acetylation; Cell Line; Cell Proliferation; Chromatin; Chromatin Immunoprecipitation; Disease-Free S | 2017 |
Histone deacetylase inhibitor (HDACi) upregulates activin A and activates the Smad signaling pathway in melanomas.
Topics: Acetylation; Activins; Antineoplastic Agents; Cell Line, Tumor; Cell Proliferation; Cell Separation; | 2018 |
An Acquired Vulnerability of Drug-Resistant Melanoma with Therapeutic Potential.
Topics: Amino Acid Transport System y+; Animals; Apoptosis; Cell Line, Tumor; Cell Proliferation; Drug Resis | 2018 |
EBV-transformed lymphoblastoid cell lines as vaccines against cancer testis antigen-positive tumors.
Topics: Antigen-Presenting Cells; Antigens, Neoplasm; Azacitidine; B-Lymphocytes; Cancer Vaccines; CD4-Posit | 2013 |
Cotargeting histone deacetylases and oncogenic BRAF synergistically kills human melanoma cells by necrosis independently of RIPK1 and RIPK3.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cell Survival; Drug Synergism; Gene Knockdown Tech | 2013 |
The NKG2D ligand ULBP2 is specifically regulated through an invariant chain-dependent endosomal pathway.
Topics: Antigens, Differentiation, B-Lymphocyte; Antigens, Surface; Biological Transport; Carbazoles; CD4-Po | 2014 |
Histone deacetylase inhibitors induce invasion of human melanoma cells in vitro via differential regulation of N-cadherin expression and RhoA activity.
Topics: Antineoplastic Agents; Apoptosis; Butyrates; Cadherins; Cell Line, Tumor; Gene Expression Regulation | 2016 |
Anti-melanoma effects of vorinostat in combination with polyphenolic antioxidant (-)-epigallocatechin-3-gallate (EGCG).
Topics: Anticarcinogenic Agents; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apop | 2010 |
Histone deacetylase inhibitors induce growth arrest and differentiation in uveal melanoma.
Topics: Animals; Antineoplastic Agents; Cell Differentiation; Cell Line, Tumor; Cell Proliferation; Chemorad | 2012 |
Selenium-containing histone deacetylase inhibitors for melanoma management.
Topics: Anilides; Anticarcinogenic Agents; Apoptosis; Caspase 3; Caspase 7; Cell Cycle Checkpoints; Cell Lin | 2012 |
BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma.
Topics: Adaptor Proteins, Signal Transducing; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 1 | 2012 |
Modulation of pro- and anti-apoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors.
Topics: Apoptosis; Apoptosis Regulatory Proteins; Cell Line, Tumor; DNA Primers; Drug Resistance, Neoplasm; | 2004 |
Vorinostat, a histone deacetylase inhibitor, enhances the response of human tumor cells to ionizing radiation through prolongation of gamma-H2AX foci.
Topics: Acetylation; Acid Anhydride Hydrolases; Antigens, Nuclear; Apoptosis; Cell Cycle; DNA Repair; DNA Re | 2006 |
Combined treatment with Ad-hTRAIL and DTIC or SAHA is associated with increased mitochondrial-mediated apoptosis in human melanoma cell lines.
Topics: Adenoviridae; Antineoplastic Agents; Apoptosis; bcl-X Protein; BH3 Interacting Domain Death Agonist | 2007 |